COLUMBIA, Md., Sept. 8 /PRNewswire-FirstCall/ -- Martek
Biosciences Corporation announced today that it will be presenting
at the upcoming UBS Global Life Sciences Conference scheduled to
take place September 20 – 22, 2010 in
New York, NY. Peter L. Buzy,
Chief Financial Officer, is scheduled to present on Wednesday, September 22, 2010 at 12:00 p.m. Eastern Time.
A live audio webcast of Martek's presentation can be accessed
at:
http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=44_F65MS6P
About Martek
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the
innovation, development, production and sale of high-value products
from microbial sources that promote health and wellness through
nutrition. The Company's technology platform consists of its core
expertise, broad experience and proprietary technology in areas
such as microbial biology, algal genomics, fermentation and
downstream processing. This technology platform has resulted in
Martek's development of a number of products, including the
company's flagship product, life'sDHA™, a sustainable and
vegetarian source of algal DHA (docosahexaenoic acid) important for
brain, heart and eye health throughout life for use in infant
formula, pregnancy and nursing products, foods and beverages,
dietary supplements and animal feeds. The Company also produces
life'sARA™ (arachidonic acid), an omega-6 fatty acid, for
use in infant formula and growing-up milks. Martek's subsidiary,
Amerifit Brands, develops, markets and distributes branded consumer
health and wellness products and holds leading brand positions in
all of its key product categories. Amerifit products are sold in
most major mass, club, drug, grocery and specialty stores and
include: Culturelle®, a leading probiotic supplement; AZO, the
leading OTC brand addressing symptom relief and detection of
urinary tract infections; and ESTROVEN®, the leading all-natural
nutritional supplement brand addressing the symptoms of menopause.
Martek currently has a number of nutritional health and wellness
products under development that it plans to commercialize and
distribute through Amerifit's distribution channels.
Martek's technology platform has also made it a sought-after
partner on a range of groundbreaking projects in process, including
the development of microbially-derived biofuels and the development
of DHA-containing oilseeds. For more information on Martek
Biosciences, visit http://www.martek.com/. For a complete list of
life'sDHA™ and life'sARA™ products, visit
http://www.lifesdha.com/. For more information about Amerifit
Brands, visit www.amerifit.com.
Cautionary Note Regarding Forward-Looking Statements
Sections of this release contain forward-looking statements.
These statements are based upon numerous assumptions which Martek
cannot control and involve risks and uncertainties that could cause
actual results to differ. These statements should be understood in
light of the risk factors set forth in the company's filings with
the Securities and Exchange Commission, including, but not limited
to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form
10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
|
Kyle Stults
|
|
|
Investor Relations
|
|
|
(410) 740-0081
|
|
|
|
SOURCE Martek Biosciences Corporation
Copyright t. 8 PR Newswire